RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB review

(RedHill Biopharma) RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva ® , ABC294640) in patients hospitalized with severe COVID-19 pneumonia has received a second unanimous recommendation to continue, following a second independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 155 patients treated for 14 days.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news